Stroke is one of the leading causes of death and disability worldwide, making early and accurate diagnosis critical to improving patient outcomes. While imaging techniques like CT scans and MRIs are widely used, they have limitations in detecting stroke at its earliest stages and may not always be accessible.

Recent research highlights the potential of blood-based biomarkers to provide valuable insights into stroke occurrence, severity, and prognosis. Biomarkers such as brain-derived tau (BD-tau), neurofilament light (NfL), glial fibrillary acidic protein (GFAP), tau, and inflammatory cytokines offer a window into neuronal injury and neuroinflammation, helping researchers and clinicians better understand stroke pathology.

This publication brief explores:

• The role of BD-tau in assessing stroke severity and predicting recovery.
• How NfL and GFAP work alongside BD-tau to improve stroke prognosis.
• The importance of ultra-sensitive biomarker detection in stroke research.
• How Simoa® technology enables precise, high-sensitivity measurement of key biomarkers.

Download the publication brief to learn more about the latest advances in blood-based biomarkers for stroke research.